2015 Peel Street
Montreal, QC H3A 1T8
Theratechnologies Inc., specialty pharmaceutical company, addresses unmet medical needs in metabolic disorders. The company’s lead product is EGRIFTA (tesamorelin for injection), an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in the United States. It also focuses on commercializing EGRIFTA in Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, Thailand, and certain central Asian countries. The company was founded in 1993 and is headquartered in Montreal, Canada.